INVITROCUE®
Transforming bioanalytics

Transforming cancer outcomes

May 2019



Disclaimer

This document does not, and does not purport to, address any or all issues which are or may be material or of interest to the Recipient in connection with its own due diligence review of the Company, or otherwise. The Recipient may not, and by receiving this document the Recipient acknowledges that it is not entitled to and agrees not to, rely on any part of this document (whether as to a matter of fact, forecast, opinion or belief) for any purpose whatsoever.

Certain statements in this document relate to the future. These forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual results, performance or achievements of the Company and the Business to be materially different from future results, performance or achievements expressed or implied by such statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. No representation, assurance or guarantee is given that the occurrence of the events expressed or implied in any forward looking statements in this document will actually occur. The forward looking statements in this document reflect views held only at the date of this document.

Past performance information given in this document is given for illustrative purposes only and should not be relied upon as (and is not) and indication of future performance. By accepting this document, the Recipient agrees that it will make and rely solely upon its own due diligence investigations and enquiries and will not in any way rely upon any of the information in this document or use this document for any purpose other than as information to assist the Recipient and its advisers to undertaken its own due diligence investigations and enquiries.

None of this statements, opinions, projections, forecasts or other forward-looking information contained in this document have been independently verified and no commitment, representation, or warranty, express or implied, is made in relation to their accuracy, reasonableness or completeness. Furthermore, where statements in this document are taken from or attributed to sources created by third parties, the Recipient should have regard to those sources and rely on its own enquiries.

Invitrocue has prepared this document based on information available to it at the time of preparation and subject to the qualifications in this document. To the maximum extent permitted by law, neither the Company nor any of its respective related bodies corporate or other affiliates, directors, officers, employees, representatives, agents, advisors or their respective advisors' affiliates or partners, directors, officers, employee or contractors (each a Limited Party and together with the Limited Parties) takes any responsibility for the contents of this documents or any action taken by the Recipient or any other person on the basis of any information in the document. The Limited Parties disclaim any obligation or undertaking to disseminate after the date of this document any updates or revisions to any forward looking statements to reflect any change in expectations in relation to those statements or any change in events, conditions or circumstances on which any such statement is based. To the maximum extent permitted by law any and all liability in respect of this document and the information contained within it is expressly excluded including without limitation any direct, indirect or consequential liability, expenses, losses, damages or costs incurred by the Recipient or any other person as a result of their receipt or use of this document or arising from the information in this document being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. No Limited Party makes any representation or warranty, express or implied, as to the currency, accuracy, completeness, reliability, fairness or correctness of the information contained in this document or about Invitrocue generally or any opportunity to invest in Invitrocue in the future.

The problem: chemotherapy does not always work

People are different



Tumours are heterogenous



(Bartek & Swanton, Nature 2013)

Unfortunately, chemotherapeutic treatments today are "one-size-fits-all."

The burden of cancer

THE GLOBAL CANCER BURDEN IS EXPECTED TO RISE TO

29.5 MILLION

in 2040

CANCER TREATMENTS **35%** ARE EFFECTIVE

WORLDWIDE CANCER DEATHS

Will increase by **71%** by 2040

TREATMENT COSTS

ARE RISING

TREATMENT OUTCOMES

HAVE NOT IMPROVED FOR MORE THAN 20 YEARS

Source: GLOBOCAN 2018

Pioneering Personalised Oncology

Addressing the vast and growing market need to improve cancer outcomes
est. US$200b for oncology by 2022*

Improving patient outcomes via evidence based decision making
Onco-PDO™ provides physicians with the missing datapoint to improve patient outcomes

First mover advantage
commercialisation of novel technology in Europe and Asia underway

Highly-scalable business model
versatile and powerful platform technology with wide applicability in multiple cancer indications

High calibre team experienced in commercialising novel technologies
supported by leading international Scientific Advisory Board

*https://www.iqvia.com/institute/reports/global-oncology-trends-2018

INVITROCUE™
Transforming bioanalytics

Onco-PDO™

Right Drug | Right Patient | Right Time



Credit: Photographed and Copyrighted by Dr Arial Zeng Yi

Onco-PDO™
How it works

- **Fresh** tumour taken from biopsy or surgery
- Panel of **over 80 approved chemotherapy drugs** available for testing on patient-derived cancer cells
- **Turnaround time of 2 weeks**, real time and clinically actionable
- **Detailed** lab report generated



Onco-PDO™ provides a key datapoint to drive more informed clinical decisions

Onco-PDO™ Benefits

Tumour avatars are **representative** of individual patient's tumour (preserves heterogeneity)

Simulates drug response of patients' cancer cells to different chemotherapies (including selected Immunotherapeutics)

Provides oncologists with **actionable insights** to inform treatment decisions

Minimizes side effects and wasted resources from **unnecessary treatments**

Onco-PDO™

Available today with multiple competitive advantages

	Patient-derived Organoids (PDO)	Patient-derived Xenografts (PDX)	Genomic Sequencing
Results in less than 2 weeks	✓	✗	✓
Predicts drug response	✓	✓	?
Cost effective	✓	✗	✓
Possibility for high throughput	✓	✗	✓
Patient-specific	✓	✓	✗

Scientific Publications Recognised by International Medical Community

Scientific data on the effectiveness of Onco-PDO™ published in multiple peer-reviewed medical journals

BioMed Research International

nature medicine

Biomaterials

nature COMMUNICATIONS

Wolters Kluwer

Global expansion strategy

- First commercial revenue for Onco-PDO™ received in **2018**
- **Increasing** number of patients utilising our test
- Global Key-Opinion-Leader education **program initiated**
- 3 international clinical **validation studies ongoing**
- **International** accreditation underway

Establishing Invitrocue laboratories in key markets to serve multiple countries

Addressable incidence rates*

Cancer Indication	Asia excl. India	Aus/NZ	Europe**
Head & Neck	437,973	9,767	97,168
Breast	515,932	22,062	237,493
Colorectal	627,329	21,217	218,938
Liver	496,213	2,921	34,601
Total	**2,077,447**	**55,967**	**588,200**

Source: World Health Organisation (WHO)

Research is ongoing with our collaborators to optimise protocols and expand indication menu.
Future indications will include: Ovarian, Lung

*Refers to absolute patient cases
**Refers to Germany, Spain, UK, Austria, Russia

INVITROCUE® Transforming bioanalytics

The markets we address

Invitrocue currently offers services in top 2 continents in cancer cases



Population	Number
Asia	8 673 444
Europe	3 911 317
North America	1 896 063
*Latin America and the Carribean	1 344 161
Africa	1 031 046
Oceania	180 870
Total	17 036 901

Onco-PDO™ is currently available in:

Asia: China, Philippines, Singapore, Thailand, Malaysia, Indonesia, Vietnam, Thailand, Australia, New Zealand

Europe: Germany, Spain, UK, Austria

Onco-PDO is available for 4 of the top 6 cancer indications worldwide



Type of cancer	Number
Lung	2 093 876
Breast	2 088 849
Colorectum	1 849 518
Prostate	1 276 106
Stomach	1 033 706
Liver	841 080
Oesophagus	572 034
Cervix Uteri	569 847
Other cancers	6 711 890
Total cases	17 036 901

Number of new cancer cases worldwide by indication, 2018

Source: http://gco.iarc.fr/today/data/factsheets/cancers/40-All-cancers-excluding-non-melanoma-skin-cancer-fact-sheet.pdf

Onco-PDO™
Our path ahead

Growing international **availability** via new partnerships in key markets

Strengthening research capabilities and relationships via broadened **advisory board**

Expanding indication menu

Ongoing **clinical data generation**

Automation to scale volume and revenue

Become standard-of-care test to be reimbursed by healthcare systems

INVITROCUE™
Transforming bioanalytics

Human liver cell services and products

Liver Cell products and offering

Pre-clinical liver assay services:

- Drug Metabolism (DMPK) assays
- Liver toxicity assays
- Infectious diseases assays testing for Hepatitis B and C
- Liver disease modeling

Humanised products:

- Fresh hepatocytes (liver cells)
- Mice carrying humanised liver cells

Rising need for *in vitro* human liver models for screening for liver disease drugs due to:

- Growing geriatric population and increasingly unhealthy lifestyle patterns driving increase in global liver disease cases
- Current lack of an available effective cure for a number of liver diseases:
  - Hepatitis B
  - Fatty liver and non-alcoholic steatohepatitis (NASH)
- Global liver disease treatment market valued at $12.4 billion in 2009, and is expected to reach $19.5 billion in 2022

Focus for 2019

- Growing number of patients using Onco-PDO™
- Establish dedicated Onco-PDO™ lab facilities to service European market
- Validate Onco-PDO™ in new cancer types
- Expand clinical datasets in multiple indications
- Grow commercial offering via complementary tests
- Launch cancer-specific proprietary kits for scale-up in other labs
- Continued revenue growth based on commercial validation of core cell-based assaying business

Reasons to invest

First mover advantage addressing large unmet market needs

- Serving the clear need for physicians and patients to improve treatment outcomes as cost of cancer soars
- Providing the datapoint to make more informed treatment decisions

International roll-out underway, driving revenue growth

- Immediate go to market model
- Test readily integrates into routine clinical practice
- Clinical validation studies underway

Clear growth prospects

- New cancer indications
- Continued international expansion
- High scalability

Growing and diversified revenue stream

- Human liver cell business and HiMICE reduces operating risks

Financial overview

Exchange/ticker	ASX: IVQ
Total ordinary shares outstanding	**525.33m**
Market Capitalization	**36.77m AUS**
Share Price	**0.07 AUS**

(As of 10 May 2019)



1. Derived from 4C report as of 30th September 2018
2. Derived from 2018 Annual Report

Led by Experienced Management Team

Dr Steven Fang, PhD, MBA
Executive Chairman and Founder

Mr Martin Bach, MBA
Vice President, Operations

Dr Sunny Tan, PhD
Senior VP Scientific Affairs & Business Development

Dr. Andreas Lindner, PhD
CEO of Invitrocue Europe AG

Global Advisory Board

Prof. Narayanan Gopalakrishna Iyer
Chair, Clinical Advisory Board
Singapore

Prof. Chng Wee Joo
Clinical Advisor
Singapore

Dr. Christian Peschel
Clinical Advisor
Germany

Dr. Stefan Paepke
Clinical Advisor
Germany

Prof. Jesús García-Foncillas
Clinical Advisor
Spain

Prof. David Waugh
Clinical and Scientific Advisor
Australia

Prof. Arial Zeng
Scientific Advisor
China

Dato' Dr. Sharifuddin Abdul Wahab
Global Insurance Advisor
Malaysia

Prof. Masakazu Toi
Clinical Advisor
Japan

Dr. Alex Matter
Pharmaceutical Advisor
Singapore

INVITROCUE®
Transforming bioanalytics

Thank You

For more information please contact:

Martin D. Bach
Martind.bach@invitrocue.com

INVITROCUE™
Transforming bioanalytics

Appendix

Board of Directors

Dr Steven Fang

Chairman and Founder

Prof. Hanry Yu

Non-Executive Director and
Scientific Mentor and Advisor

Ms Ng Ee Ting

Non-Executive Director

Dr Gary Pace

Non-Executive Director
Former Director of
ResMed

Dr Andreas Lindner

CEO of Invitrocue Europe AG

Mr Kit Wei Lui

Non-Executive Director

Business model overview

Onco-PDO™

- Targeted and personalised approach to cancer treatments
- Ranks the therapeutic options best suited for each individual's cancer
- Developed in collaboration with A*STAR's Genome Institute of Singapore
- Commercialised in Europe and Asia
- International clinical validation studies underway

Human Liver Services and Products

- Well-established, revenue generating business unit
- Engineering in vitro & in vivo liver models for safety and efficacy testing
- Predictive in vitro models for biotech, pharmaceutical industry, and consumer health companies
- Reduces clinical trial spend by highlighting liver toxicity early in development phase